Nov. 23, 2012 (China Knowledge) - BioTech Pharmaceuticals Co Ltd, which mainly engages in the R&D and production of monoclonal antibodies and vaccines against malignant tumor, has said its output value for the first nine month of this year to exceed RMB 400 million, more than it realized in the whole of last year. It expects to achieve RMB 465 million in revenue by end 2012.
In August 2008, BioTech Pharma built its headquarters in Beijing E-Town
, a triple-A rated industrial park
. That same year, the company published China's first humanized therapeutic monoclonal antibody known as Nimotuzumab. Currently, over 13,000 Chinese patients have benefitted from this antibody.
As one of the pillar industrial in Beijing E-Town
, the industrial park
's biomedical pharmaceutical industry had attracted 193 enterprises comprising 12 in chemical medicine, 8 in traditional Chinese medicine, 11 in biomedicine, 31 in medical equipment and 131 from CRO. Many famous enterprises such as Bayer Healthcare, Sanofi-Aventis and Tongrentang are also found in the park.
Last year, Beijing E-Town
saw its biomedical industry generated RMB 19.73 billion in output value, accounted for 48% of Beijing's total. Nine biomedical companies in the park are listed in the Top 50 Enterprises by tax contribution in 2011.
In the first half of 2012, the industrial park
output value from biomedical industry reach RMB 10.25 billion, up 8.1% YoY and accounting for nearly 10% of the industrial park's total.
On Oct 18, 2011, Beijing E-Town
formally launched its biomedical park. With a total investment of over RMB 900 million the park can absorb more than 100 biomedical CRO companies. The biomedical park is able to provide development space for foreign and domestic R&D institutions as well as overseas talent in biomedical field.
According to Beijing E-Town
's 12th Five-Year plan, the park will strive to develop biomedicine, traditional Chinese medicine, chemical drug and medical equipment industry as well as to promote the development of CRO and CMO. Beijing E-Town
is also actively promoting to the world’s famous bioengineering and medicine companies to accelerate its development of local enterprises to form a world-class biomedical industry cluster.